Theriva Biologics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TOVX American 8731 https://therivabio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Theriva Biologics Inc

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery - May 23rd, 2023 12:00 pm
Q1 2023 Theriva Biologics Inc Earnings Call - May 12th, 2023 2:22 am
Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results - May 11th, 2023 12:00 pm
Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results - May 4th, 2023 12:00 pm
Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - Apr 13th, 2023 12:00 pm
Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results - Mar 30th, 2023 12:00 pm
Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results - Mar 24th, 2023 8:05 pm
Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results - Mar 20th, 2023 12:00 pm
Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - Feb 16th, 2023 5:05 pm
Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference - Jan 17th, 2023 9:05 pm
Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - Jan 17th, 2023 1:00 pm
Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors - Jan 9th, 2023 1:00 pm
Sidoti's December Small-Cap Virtual Conference - Dec 6th, 2022 12:00 pm
Theriva Biologics to Participate in Upcoming Investor Conferences - Dec 1st, 2022 1:00 pm
Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results - Nov 10th, 2022 9:45 pm
Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results - Nov 10th, 2022 12:00 pm
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results - Nov 3rd, 2022 8:05 pm
Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - Nov 3rd, 2022 12:00 pm
Theriva Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus Therapeutics - Oct 31st, 2022 12:00 pm
Theriva Biologics Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck - Oct 24th, 2022 12:00 pm